HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.

Abstract
Parkinsonian symptoms arise due to over-activity of the indirect striatal output pathway, and under-activity of the direct striatal output pathway. l-DOPA-induced dyskinesia (LID) is caused when the opposite circuitry problems are established, with the indirect pathway becoming underactive, and the direct pathway becoming over-active. Here, we define synaptic plasticity abnormalities in these pathways associated with parkinsonism, symptomatic benefits of l-DOPA, and LID. We applied spike-timing dependent plasticity protocols to cortico-striatal synapses in slices from 6-OHDA-lesioned mouse models of parkinsonism and LID, generated in BAC transgenic mice with eGFP targeting the direct or indirect output pathways, with and without l-DOPA present. In naïve mice, bidirectional synaptic plasticity, i.e. LTP and LTD, was induced, resulting in an EPSP amplitude change of approximately 50% in each direction in both striatal output pathways, as shown previously. In parkinsonism and dyskinesia, both pathways exhibited unidirectional plasticity, irrespective of stimulation paradigm. In parkinsonian animals, the indirect pathway only exhibited LTP (LTP protocol: 143.5±14.6%; LTD protocol 177.7±22.3% of baseline), whereas the direct pathway only showed LTD (LTP protocol: 74.3±4.0% and LTD protocol: 63.3±8.7%). A symptomatic dose of l-DOPA restored bidirectional plasticity on both pathways to levels comparable to naïve animals (Indirect pathway: LTP protocol: 124.4±22.0% and LTD protocol: 52.1±18.5% of baseline. Direct pathway: LTP protocol: 140.7±7.3% and LTD protocol: 58.4±6.0% of baseline). In dyskinesia, in the presence of l-DOPA, the indirect pathway exhibited only LTD (LTP protocol: 68.9±21.3% and LTD protocol 52.0±14.2% of baseline), whereas in the direct pathway, only LTP could be induced (LTP protocol: 156.6±13.2% and LTD protocol 166.7±15.8% of baseline). We conclude that normal motor control requires bidirectional plasticity of both striatal outputs, which underlies the symptomatic benefits of l-DOPA. Switching from bidirectional to unidirectional plasticity drives global changes in striatal pathway excitability, and underpins parkinsonism and dyskinesia.
AuthorsSherri L Thiele, Betty Chen, Charlotte Lo, Tracey S Gertler, Ruth Warre, James D Surmeier, Jonathan M Brotchie, Joanne E Nash
JournalNeurobiology of disease (Neurobiol Dis) Vol. 71 Pg. 334-44 (Nov 2014) ISSN: 1095-953X [Electronic] United States
PMID25171793 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCrown Copyright © 2014. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antiparkinson Agents
  • Dopamine Agents
  • Purinergic Agents
  • Receptor, Adenosine A2A
  • Receptors, Dopamine D1
  • Green Fluorescent Proteins
  • Levodopa
  • Oxidopamine
Topics
  • Animals
  • Animals, Newborn
  • Antiparkinson Agents (adverse effects)
  • Corpus Striatum (pathology)
  • Disease Models, Animal
  • Dopamine Agents (pharmacology)
  • Dyskinesia, Drug-Induced (etiology, pathology)
  • Excitatory Postsynaptic Potentials (drug effects)
  • Functional Laterality
  • Green Fluorescent Proteins (genetics, metabolism)
  • In Vitro Techniques
  • Levodopa (adverse effects)
  • Mice
  • Mice, Transgenic
  • Neural Pathways (pathology)
  • Neuronal Plasticity (drug effects, physiology)
  • Oxidopamine (toxicity)
  • Parkinsonian Disorders (chemically induced, drug therapy)
  • Purinergic Agents (pharmacology)
  • Receptor, Adenosine A2A (genetics, metabolism)
  • Receptors, Dopamine D1 (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: